BioCentury -- SymBio Pharmaceuticals Ltd. (Tokyo, Japan) raised Y2 billion ($24 million) in a series E round led by existing investors Cephalon Inc. (NASDAQ:CEPH) and JAFCO. Last December, SymBio launched Treakisym bendamustine (SyB L-0501) in Japan to treat refractory and relapsed indolent non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma. SymBio said it plans to develop the alkylating agent for other hematological indications, including aggressive NHL and multiple myeloma.
